Qualigen Therapeutics (QLGN) is announcing an update on patents granted in the first six months of 2025. The patent is Titled “Substitued Naphthalene Diimides and Their Use.” The patent is for the drug, which was developed by Professor Stephen Neidle and his team at the University College of London, and is licensed by Qualigen Therapeutics, QN-302. These patents cover the product and their methods of manufacturing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QLGN: